LANTHEUS HOLDINGS INC

NASDAQ: LNTH (Lantheus Holdings, Inc.)

Kemas kini terakhir: 02 Jan, 8:36AM

66.40

-0.15 (-0.23%)

Penutupan Terdahulu 66.55
Buka 66.80
Jumlah Dagangan 9,197
Purata Dagangan (3B) 1,254,451
Modal Pasaran 4,514,811,904
Harga / Pendapatan (P/E TTM) 27.55
Harga / Pendapatan (P/E Ke hadapan) 12.17
Harga / Jualan (P/S) 3.08
Harga / Buku (P/B) 3.98
Julat 52 Minggu
47.25 (-28%) — 111.29 (67%)
Tarikh Pendapatan 6 Nov 2025
Margin Keuntungan 16.55%
Margin Operasi (TTM) 27.38%
EPS Cair (TTM) 3.51
Pertumbuhan Hasil Suku Tahunan (YOY) 0.80%
Pertumbuhan Pendapatan Suku Tahunan (YOY) -44.30%
Jumlah Hutang/Ekuiti (D/E MRQ) 52.78%
Nisbah Semasa (MRQ) 5.74
Aliran Tunai Operasi (OCF TTM) 525.08 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 241.87 M
Pulangan Atas Aset (ROA TTM) 14.39%
Pulangan Atas Ekuiti (ROE TTM) 24.11%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - Specialty & Generic (US) Bercampur Menaik
Drug Manufacturers - Specialty & Generic (Global) Menaik Menaik
Stok Lantheus Holdings, Inc. Menaik Menurun

AISkor Stockmoo

2.1
Konsensus Penganalisis 3.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal 0.0
Osilator Teknikal 3.5
Purata 2.13

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
LNTH 5 B - 27.55 3.98
KNSA 3 B - 93.91 5.58
HROW 2 B - - 35.03
BCRX 2 B - - 56.59
ALVO 1 B - 20.63 -
AMLX 1 B - - 5.60

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Sektor Healthcare
Industri Drug Manufacturers - Specialty & Generic
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 2.24%
% Dimiliki oleh Institusi 116.12%
Julat 52 Minggu
47.25 (-28%) — 111.29 (67%)
Julat Harga Sasaran
72.00 (8%) — 82.00 (23%)
Tinggi 82.00 (Truist Securities, 23.49%) Beli
Median 77.00 (15.96%)
Rendah 72.00 (Mizuho, 8.43%) Beli
Purata 77.00 (15.96%)
Jumlah 2 Beli
Harga Purata @ Panggilan 65.04
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Truist Securities 18 Dec 2025 82.00 (23.49%) Beli 64.84
12 Dec 2025 80.00 (20.48%) Beli 66.62
Mizuho 17 Dec 2025 72.00 (8.43%) Beli 65.24

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
12 Jan 2026 Pengumuman Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Iovance Biotherapeutics, Inc. (IOVA), Nutex Health, Inc. (NUTX), Lantheus Holdings, Inc. (LNTH), and Molina Healthcare, Inc. (MOH)
02 Jan 2026 Pengumuman Lantheus Announces Closing of SPECT Business Sale to SHINE Technologies
24 Nov 2025 Pengumuman Lantheus to Present Florbetaben F 18 Data at CTAD 2025
10 Nov 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
07 Nov 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
06 Nov 2025 Pengumuman Lantheus Reports Third Quarter 2025 Financial Results and Provides Business Update
06 Nov 2025 Pengumuman Lantheus Announces Leadership Transition Plan
04 Nov 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
03 Nov 2025 Pengumuman INVESTOR DEADLINE NEXT WEEK: RGRD LLP Announces that Lantheus Holdings, Inc. (LNTH) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
31 Oct 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
30 Oct 2025 Pengumuman Shareholders SueWallSt in New Class Action Against Lantheus Holdings, Inc. - Act Now
30 Oct 2025 Pengumuman Lantheus Announces FDA Grants PDUFA Date for LNTH-2501 (Ga 68 edotreotide), a PET Diagnostic Imaging Kit Targeting Somatostatin Receptor-Positive (SSTR+) Neuroendocrine Tumors (NETs)
28 Oct 2025 Pengumuman Lantheus Announces FDA Acceptance of New Drug Application for MK-6240, a PET Imaging Agent Targeting Tau in Alzheimer’s Disease
27 Oct 2025 Pengumuman Investors SueWallSt as Lantheus Holdings, Inc. Faces Securities Fraud Allegations
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda